NHS Progress and Business Update

Feedback PLC

20 April 2026

 

Feedback plc

NHS Progress and Business Update

Significant scale opportunities as positive discussions continue and further funding awarded

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces an update on the Company's continued dialogue with NHS stakeholders with a view to fulfilling productivity requirements across the NHS.

Previous indications were that a central NHS decision would be made in relation to a potential contract for adoption of a widescale programme for Bleepa around the end of the 2025/26 NHS financial year (31 March 2026). The Company now understands that decisions will be delayed by at least 6-9 months due to NHS internal factors. Nevertheless, discussions have continued to progress positively with central NHS stakeholders regarding at scale opportunities for Bleepa which the Board believes have the potential to be aligned to new frontline digitisation funding which is expected to become available in the 2026/27 NHS financial year.

Despite the delayed decision, NHSE has extended Bleepa's existing licences at Queen Victoria Hospital NHS Foundation Trust ("QVH") (annualised contract value £495k) to cover the 9-month period ending in December 2026. This ensures that the Bleepa pathway programme can continue to expand within Sussex whilst discussions continue around the potential for a larger scale rollout. Bleepa's usage at QVH continues to grow in both user numbers and use cases. The Company recently partnered with Patients Know Best to deliver a pioneering new insomnia pathway in Sussex, and we are in active discussions with QVH around additional use cases, product optimisation and additional funding in this calendar year.

Focus on Core Growth Opportunities

Following discussion with the Royal Berkshire NHS Foundation Trust, the Company will not be renewing its contract for photocapture with the Trust which came to the end of its 3-year term at the end of March 2026. This is part of a managed process to focus on utilising internal resources to optimise Bleepa for core pathway opportunities which the Company believes have the potential to deliver significantly larger revenues.

The Bleepa pathway use case is also being demonstrated for internal pathways at the Northern Care Alliance NHS Foundation Trust where the Company has agreed a further annual contract extension with the Trust, providing the opportunity to further build the business case for expansion and funding opportunities.

The Board remains confident that the Company continues to provide a unique value proposition that could deliver significant impact against the NHS' primary objective of waitlist reduction and elective recovery. The Company remains in active dialogue with national NHS stakeholders underpinning confidence in the mid-term opportunity for Bleepa. The Company's cash position is being carefully managed and, based on current plans, provides a runway extending to mid-2027.

Dr Tom Oakley, CEO of Feedback, said:

"Despite the delay in the NHS's decision, we remain optimistic of a positive outcome. The additional funding to extend Bleepa licences at QVH demonstrates an ongoing commitment to our solutions.

"Whilst we await the outcomes of central NHS decisions, we will focus on expanding the programme at QVH and other pathway opportunities, whilst selectively exploring alternative opportunities to create shareholder value."

Enquiries:

Feedback plc Tom Oakley, CEO Emma Oswick, CFO	[phone] [e-mail]
Panmure Liberum Limited (NOMAD and Broker) Emma Earl/Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Walbrook PR Ltd;	Tel: [phone] or [e-mail]
Nick Rome/Marcus Ulker	07748 325 236 or 07867 984 082

About Feedback plc

Feedback plc is the strategic partner to unlock productivity in health and care through digital connectivity and asynchronous collaboration. With proven expertise in system integration, we enable teams to work flexibly, share information securely, and deliver care more efficiently.

Bleepa® is an award-winning collaboration platform that improves the quality and productivity of patient pathways enabling health and care organisations to hit targets with their existing clinical workforce. We achieve this by connecting digital infrastructure across systems, enabling asynchronous working, reducing geographic barriers and removing unnecessary appointments.

Bleepa supports the shift from analogue to digital and from hospital to community-based care, by uniting essential data and teams to enhance clinical decision making and enable better coordinated care.

The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

https://fbk.com

 

END